AMENDED PRIVATE SECURITIES PURCHASE AND ASSIGNMENT AGREEMENTPrivate Securities Purchase and Assignment Agreement • October 21st, 2019 • Accelerated Pharma, Inc. • Pharmaceutical preparations • New York
This PRIVATE SECURITIES PURCHASE AND ASSIGNMENT AGREEMENT (the “Agreement”), dated as of January 17, 2019, is by and between Alpha Capital Anstalt (“Alpha”), organized under the laws of Liechtenstein, with offices located at Lettstrasse 32, 9490 Vaduz, Liechtenstein and Brio Capital Master Fund Ltd (“Brio”), organized under the laws of the Cayman Islands with offices located at 100 Merrick Road, Suite 401, W. Rockville Center, NY 11570 (each of Alpha and Brio may be referred to collectively, as the “Purchasers” and individually, as a “Purchaser”), on the one hand, and Firstfire Global Opportunities Fund, LLC (“Firstfire”), a New York limited liability company, with offices at 1040 First Avenue, Suite 190, New York, NY 10022 and Efrat Investments LLC, a Delaware limited liability company with offices located at 54 Lenox Avenue, Clifton NJ 07014 (“Efrat”), on the other hand, and Accelerated Pharma, Inc., a Delaware corporation with offices located at 15W155 81st Street, Burr Ridge, IL 60
Amended Bridge Debt Financing AgreementBridge Debt Financing Agreement • October 21st, 2019 • Accelerated Pharma, Inc. • Pharmaceutical preparations
This Amended Bridge Debt Financing Agreement, dated as of this 1st day of June 1, 2019 (the “Agreement”), effective as of November 1, 2018, is by and between Accelerated Pharma, Inc., a Delaware corporation with offices located at 15W155 81st Street, Burr Ridge, IL 60507 (the “Borrower”), on the one hand, and one or more lenders whose signature are attached on Schedule A hereto, (each a “Lender” and collectively, the “Lenders).
AMENDED NOTE EXTENSION AGREEMENTNote Extension Agreement • October 21st, 2019 • Accelerated Pharma, Inc. • Pharmaceutical preparations
This Amended Note Extension Agreement (“Amended Extension Agreement”), is made and entered into this 30th day of May 2019, effective as of January 30, 2019 (the “Effective Date”), by and among Accelerated Pharma, Inc., a Delaware corporation (the “Company”), and the parties (each a “Note Holder” and collectively, the “Note Holders”) identified on the Note Holder Conversion Schedule attached hereto. The Company and the Note Holders are sometimes referred to individually, as a “Party” and collectively, as the “Parties.”
